Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PCO371 (2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-) is an orally active full agonist of parathyroid hormone receptor 1. It has no effect on PTH type 2 receptor.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,500 | |||
5 mg | 在庫あり | ¥ 57,000 | |||
10 mg | 在庫あり | ¥ 91,500 | |||
25 mg | 在庫あり | ¥ 152,500 | |||
50 mg | 在庫あり | ¥ 217,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 80,000 |
説明 | PCO371 (2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-) is an orally active full agonist of parathyroid hormone receptor 1. It has no effect on PTH type 2 receptor. |
In vitro | In COS-7 cells expressing hPTHR1, PCO371 causes cAMP production (EC50: 2.4?μM). 2.5 μM in COS-7 cells transfected with hPTHR1-delNT, and also enhances the phospholipase C activity (EC50, 17?μM)[1]. |
別名 | 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl- |
分子量 | 635.65 |
分子式 | C29H32F3N5O6S |
CAS No. | 1613373-33-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 120 mg/mL (188.78 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PCO371 1613373-33-3 Endocrinology/Hormones Thyroid hormone receptor(THR) 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl- PCO-371 inhibit Inhibitor THR PCO 371 Thyroid Hormone Receptor inhibitor